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ABSTRACT
Objective Studies describe COVID-19 patient 
characteristics and outcomes across populations, but 
reports of variation across healthcare facilities are 
lacking. The objectives were to examine differences in 
COVID-19 patient volume and mortality across facilities, 
and understand whether facility variation in mortality 
was due primarily to differences in patient versus facility 
characteristics.
Design Observational cohort study with multilevel mixed 
effects logistic regression modelling.
Setting The Veterans Health Administration (VA) is the 
largest healthcare system in the USA.
Participants Patients with COVID-19.
Main outcome All- cause mortality within 45 days after 
COVID-19 testing (March–May, follow- up through 16 July 
2020).
Results Among 13 510 patients with COVID-19, 3942 
(29.2%) were admitted (2266/3942 (57.5%) ward; 
1676/3942 (42.5%) intensive care unit (ICU)) and 
679/3942 (17.2%) received mechanical ventilation. 
Marked heterogeneity was observed across facilities 
in median age (range: 34.3–83.9 years; facility mean: 
64.7, SD 7.2 years); patient volume (range: 1–737 at 
160 facilities; facility median: 48.5, IQR 14–105.5); 
hospital admissions (range: 1–286 at 133 facilities; 
facility median: 11, IQR 1–26.5); ICU caseload (range: 
1–85 at 115 facilities; facility median: 4, IQR 0–12); and 
mechanical ventilation (range: 1–53 at 90 facilities; facility 
median: 1, IQR 0–5). Heterogeneity was also observed 
in facility mortality for all patients with COVID-19 (range: 
0%–29.7%; facility median: 8.9%, IQR 2.4%–13.7%); 
inpatients (range: 0%–100%; facility median: 18.0%, IQR 
5.6%–28.6%); ICU patients (range: 0%–100%; facility 
median: 28.6%, IQR 14.3%–50.0%); and mechanical 
ventilator patients (range: 0%–100%; facility median: 
52.7%, IQR 33.3%–80.6%). The majority of variation in 
facility mortality was attributable to differences in patient 
characteristics (eg, age).
Conclusions Marked heterogeneity in COVID-19 patient 
volume, characteristics and mortality were observed 
across VA facilities nationwide. Differences in patient 
characteristics accounted for the majority of explained 
variation in mortality across sites. Variation in unadjusted 
COVID-19 mortality across facilities or nations should be 
considered with caution.
BACKGROUND
Although studies have described the clinical 
characteristics of patients with COVID-19, 
outcome rates, and predictors of adverse 
outcomes across diverse populations in 
various countries, these reports have generally 
focused only on the population level—not the 
facility level.1–4 Reports have described varia-
tion in outcomes of patients with COVID-19 
across geographic regions and over time, 
generally reporting higher mortality early in 
the pandemic.5 Studies have also examined 
the association between patient characteristics 
and outcomes, for example, consistently iden-
tifying an association between older age and 
increased mortality for patients with COVID-
19.6 Although a few studies have examined 
facility characteristics that are associated with 
Strengths and limitations of this study
 ► Observational cohort study from the largest health-
care system in the USA.
 ► Focus on the facility level.
 ► Evaluated care of COVID-19 positive Veteran patients 
at US Department of Veterans Affairs (VA) facilities; 
findings should not be generalised to patients cared 
for in non- VA facilities.
 ► Described the proportion of patients who were treat-
ed in an intensive care unit or received mechanical 
ventilation, we cannot comment on the appropriate-
ness of such care.
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COVID-19 outbreaks within nursing homes,7 8 evaluations 
of the relative contribution of facility- level characteristics 
and patient characteristics to patient outcomes have been 
lacking.
The US Veterans Health Administration (VA) is the 
largest integrated healthcare system in the USA, providing 
care for approximately 6.1 million Veteran patients within 
170 diverse medical centres.9 10 VA medical centres are 
dispersed across the USA and vary in terms of size and 
services provided. Given that the burden of COVID-19 
disease has varied across US communities, we sought to 
describe the variety in experiences of the 160 VA medical 
centres that have provided care for patients with COVID-
19. We had two objectives: (1) to describe observed vari-
ation between facilities in terms of overall COVID-19 
patient volume, hospital admissions, intensive care unit 
(ICU) admissions and mechanical ventilation; and (2) to 
examine the degree to which variance in mortality could 
be explained by patient- level versus facility- level char-
acteristics by constructing models estimating mortality 
among patients with COVID-19 based on patient charac-
teristics, care setting (eg, outpatient, inpatient admission 
and ICU) and facility characteristics.
METHODS
Cohort construction
This observational cohort included all Veteran patients 
(outpatients and inpatients) with a positive COVID-19 
test date during the period 1 March 2020–31 May 2020 
and followed them for 45 days after the positive test 
(follow- up period through 16 July 2020). We included 
Veterans tested in a VA laboratory with COVID-19 positive 
tests (PCR or antigen testing) and Veterans tested outside 
of the VA using data from the VA National Surveillance 
Tool (VA- NST). The VA- NST is a registry that extracts 
COVID-19 cases in near real time using a combination of 
laboratory results and natural language processing (NLP) 
on clinical notes and other documents in the medical 
record.
In addition, we excluded: patients with a positive anti-
body test prior to a positive PCR test and non- Veteran 
patients tested or receiving care at a VA facility (ie, human-
itarian cases). We assigned patients to the facility where 
they obtained their COVID-19 positive test for the descrip-
tion of overall caseload and to the facility where they were 
admitted for the analyses that included care setting (note: 
VA facilities span the spectrum from providing primarily 
outpatient or domiciliary care whereas others provide 
tertiary care including critical care).
Data sources
Electronic health record data
Corporate Data Warehouse (CDW) data include infor-
mation from the Veterans Information Systems and 
Technology Architecture (VistA). VistA is the electronic 
medical record system used across the VA system.11 CDW 
data included: inpatient and outpatient data files (eg, 
clinical encounters with diagnostic and procedure codes) 
in the 2 years prior to the COVID-19 positive test date to 
identify past medical history,12 healthcare utilisation and 
procedures; vital signs; laboratory data; orders; and medi-
cations. The date of death was obtained from multiple 
sources, including: CDW data; the VA Vital Status File, 
which uses VA and non- VA sources to identify dates of 
death for VA beneficiaries; inpatient records that indi-
cated a death disposition; note titles; and chart review.13 
Facility complexity data were obtained from the VA Office 
of Productivity, Efficiency and Staffing: facilities are clas-
sified into five levels (1a, 1b, 1c, 2 or 3) where level 1a 
is the most complex and level 3 is the least complex.14 
Complexity level is based on multiple domains including 
ICU level, operative complexity, teaching status, research, 
clinical programme offerings (eg, interventional cardiac 
catheterisation, transplant, interventional radiology and 
polytrauma), multicampus status, rurality, community 
care and mental health services. ICU level is scored from 
1 (no ICU) to 5 (a level 1 ICU).
Hospital admission
VA hospital admission status was identified either after 
the COVID-19 test date or prior to the COVID-19 test, 
if the patient was already hospitalised at the time of the 
testing.
Outcome: 45-day mortality
Zero- time was the date of the positive COVID-19 test. 
The primary outcome was all- cause mortality within 45 
days of the positive COVID-19 test. We chose the 45- day 
time frame because our chart review indicated that some 
patients who died from COVID-19 disease would have 
been omitted by using a 30- day time horizon.
Chart review validation of electronic health record data
We conducted chart reviews on samples of patients 
with COVID-19 to validate the electronic health record 
data. The chart reviews were conducted iteratively. For 
example, we validated the COVID-19 positive laboratory 
test status for 31 patients to ensure that our approach to 
identifying patients with COVID-19 excluded patients 
who had non- COVID-19 coronavirus laboratory testing 
(eg, human coronavirus types 229E, NL63, OC43 and 
HKU1).
Chart reviews were also conducted to confirm positive 
test status for non- VA laboratory tests that were included 
in the VA- NST data. We conducted chart reviews on a 
sample of 217 charts of patients included in the VA- NST 
who were not included in VA laboratory data. Chart reviews 
confirmed that the positive test result in the VA- NST was 
accurate (ie, a true COVID-19 case). However, the date 
of positive test was not consistently accurate (because 
the VA- NST uses NLP and other approaches to iden-
tify case status, the first note in the VA medical record 
about COVID-19 may actually reference testing that was 
conducted in the non- VA setting days or weeks prior to 
the date recorded in the VA- NST).
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To ensure that we had complete mortality data, we 
developed an algorithm validated through chart review. 
To validate inpatient mortality, we conducted chart 
reviews on all patients admitted at two large VA hospitals 
in diverse geographic regions and confirmed that the 
death information from the various CDW files included 
mortality status for all inpatients who had died during 
their hospital stay. To validate mortality in the postdis-
charge period, we conducted chart review on all patients 
who were discharged alive from a VA facility but who had 
neither new laboratory tests nor were not readmitted 
(both indicators that the patient was alive). To validate 
mortality in the outpatient setting, we examined 200 
charts and 55 facilities searching for mortality status 
evidence. The mortality algorithm we developed identi-
fied 103 of the 111 (92.8%) deaths, which were identified 
by chart review.
Statistical analysis
Our analyses were conducted over two main phases. First, 
we examined unadjusted, observed heterogeneity in 
patient volume (ie, the number of patients with COVID-
19) across VA facilities. Specifically, we evaluated total 
COVID-19 patient volume, number of patients admitted 
to the hospital, ICU patient volume and number of 
patients who were mechanically ventilated. Similarly, we 
examined unadjusted, observed heterogeneity in 45- day 
mortality across VA facilities.
Second, we sought to examine differences in mortality 
across facilities after risk adjustment. We began by exam-
ining patient- level differences in baseline characteristics 
among patients with COVID-19 who were admitted versus 
not admitted to the hospital, and among patients who 
died versus those who survived 45 days from the COVID-19 
positive test date. χ2 tests and Wilcoxon rank- sum tests 
were used to compare differences in categorical variables. 
We calculated the Spearman correlation coefficient for 
the association between baseline characteristics (eg, age) 
and mortality. Next, we used mixed effects logistic regres-
sion modelling to estimate 45- day patient- level mortality 
across VA facilities with a random effect for facility. We 
tested four models. Model 1 adjusted only for baseline 
patient characteristics (eg, age). Model 2 included patient 
and facility characteristics (to examine relative contribu-
tion of the facility characteristics). Model 3 added where 
the setting where the patient received care (eg, inpatient 
ward vs ICU) to model 1. Model 4 added facility charac-
teristics to model 3. Finally, we examined the variance in 
facility mortality across models to explore the degree to 
which differences in mortality across facilities was associ-
ated with patient- level versus facility- level characteristics.
We conducted sensitivity analyses by restricting the 
cohort only to Veteran patients with a positive COVID-19 
test at a VA laboratory (excluding patients who were 
only identified in the VA- NST because of our inability 
to confirm the dates of the COVID-19 tests) and also 
excluded patients residing in VA Community Living 
Centers (CLC) at the time of the COVID-19 positive test 
(because some COVID-19 CLC patients were transferred 
to a different VA for admission, and other patients were 
retained within the same facility but moved from the 
CLC unit to the acute care part of the hospital). We also 
used proportional hazard modelling mortality across the 
same 45- day time frame as in the main analysis as a confir-
matory analysis. All analyses were performed using SAS 
Enterprise Guide V.7.11.
Data availability
These data must remain on VA servers. No data are avail-
able. In the interest of data transparency, investigators 
interested in working with the data are encouraged to 
contact the corresponding author.
Ethics approval
A waiver of informed consent and Health Insurance 
Portability and Accountability Act (HIPAA) authorisation 
were granted for the collection of medical record data.
Patient and public involvement
No patients or members of the public were involved in 
the design or conduct of this study. Results will be distrib-
uted to VA leadership at the national and regional levels.
RESULTS
Among 13 510 COVID-19 positive Veterans: 3942 (29.2%) 
were admitted to a VA hospital, either to an inpatient 
ward (2266/3942 (57.5%)) or to ICU (1676/3942 
(42.5%)); and 679/3942 (17.2%) received mechanical 
ventilation. A total of 493/13 510 (3.6%) patients were 
hospitalised at the time of their COVID-19 testing. The 
median time from COVID-19 test to admission (among 
patients for whom the test was performed before or on 
the day of admission) was 0 days (IQR 0–1). A total of 
276/13 510 (2.0%) patients (at 30 VA facilities) obtained 
their COVID-19 positive test at one VA facility but were 
admitted to a different hospital.
Heterogeneity in caseload across VA facilities
Substantial heterogeneity in COVID-19 caseload was 
observed (figure 1). COVID-19 patient volume ranged 
from 1 to 737 across 160 VA facilities (facility median: 48.5, 
IQR 14–105.5). Hospital admissions ranged from 1 to 286 
(facility median: 11, IQR 1–26.5) with at least one patient 
being admitted at 133 facilities. ICU caseload ranged from 
0 to 85 across facilities (facility median: 4, IQR 0–12) with 
at least one patient being admitted to the ICU at 115 facil-
ities. Among the 133 facilities with at least one COVID-19 
hospital admission, the proportion of patients within a 
facility who were cared for in the ICU ranged from 0% 
to 77.8%. The number of patients requiring mechanical 
ventilation ranged from 0 to 53 across facilities (facility 
median: 1, IQR 0–5) with patients receiving mechanical 
ventilation at 90 facilities. Among the 115 facilities with 
at least one COVID-19 ICU admission, the proportion of 
patients within a facility who received mechanical ventila-
tion ranged from 0% to 55.6%.
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Heterogeneity in case-mix across VA facilities
Heterogeneity across facilities in factors that have been 
associated with poor COVID-19 outcomes was also 
observed (online supplemental figure A). For example, 
the median age of patients with COVID-19 by facility varied 
from 34.3 to 83.9 years (mean across facilities: 64.7±SD, 
7.2 years). The facility median age was <50 years at 5/160 
(3.1%) facilities, ≥50 but <60 years at 24/160 (15.0%) 
facilities, ≥60 but <70 years at 94/160 (58.8%) facilities 
and ≥70 years for 37/160 (23.1%) facilities. In unadjusted 
analyses, older patients were more likely to be admitted 
than younger patients (table 1). For example, only 14.7% 
(520/3549) of patients with COVID-19 who were <55 years 
old were admitted to the hospital, but 35.4% (504/1422) 
of patients ≥85 years old were admitted (p<0.001). In 
unadjusted analyses, older patients were also more like 
to die than younger patients (table 1): 1.0% (34/3549) of 
patients with COVID-19 <55 years old died within 45 days 
of the COVID-19 positive laboratory test compared with 
33.8% (481/1422) mortality among patients ≥85 years old 
(p<0.001; online supplemental figure B). Several patient 
characteristics were more common among patients with 
COVID-19 who were admitted to the hospital including: 
black race; male gender; history of hypertension, diabetes, 
chronic obstructive pulmonary disease (COPD), chronic 
kidney disease (CKD), congestive heart failure (CHF), 
atrial fibrillation, cancer and myocardial infarction (MI); 
current smoking; low body mass index (<25 kg/m2); and 
residence in a long- term care facility (table 1).
Heterogeneity in observed mortality across VA facilities
The unadjusted, observed facility 45- day all- cause 
mortality rate for all patients with COVID-19 ranged from 
0% to 29.7% (facility median: 8.9%, IQR 2.4%–13.7%). 
Among facilities with at least 10 patients with COVID-19, 
the mean facility mortality rate was 10.1% (SD of 6.3%). 
The facility mortality rate for patients with COVID-19 who 
were admitted to the hospital ranged from 0% to 100% 
(facility median: 18.0%, IQR 5.6%–28.6%). Among facil-
ities with at least 10 patients with COVID-19 who were 
admitted to the hospital, the mean facility mortality rate 
among admitted patients was 20.7% (SD of 10.7%). In 
contrast, the facility mortality for patients with COVID-19 
who were not admitted ranged from 0% to 32.1% (facility 
median: 3.6%, IQR 0%–8.3%). The facility mortality 
for COVID-19 ICU patients ranged from 0% to 100% 
(facility median: 28.6%, IQR 14.3%–50.0%). Among 
facilities with at least 10 patients with COVID-19 in the 
ICU, the mean facility mortality rate for ICU patients was 
32.7% (SD of 14.3%). The facility mortality for patients 
with COVID-19 requiring mechanical ventilation ranged 
from 0% to 100% (facility median: 52.7%, IQR 33.3%–
80.6%). Figure 2 displays the unadjusted mortality rates 
with patient volume for each facility. In general, facilities 
Figure 1 The figure displays the total number of COVID-19 Veteran patients across US Veterans Health Administration facilities 
(panel A; n=160 facilities had at least one COVID-19 positive patient), the number of hospital admissions (panel B; n=133 
facilities had at least one COVID-19 hospital admission), the number of patients cared for in an intensive care unit (ICU) per 
facility (panel C; n=115 facilities had at least one ICU admission); and the number of patients with mechanical ventilation (panel 
D; n=90 facilities had at least one patient on a mechanical ventilator).
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Died within 45 
days (n=1467)
P value
Column Row Row Row Row
N (%) N (%) N (%) N (%) N (%)
Age (years) <0.001 <0.001
  <55 3549 (26.3) 3029 (85.4) 520 (14.6) 3515 (99.0) 34 (1.0)
  55–64 2872 (21.3) 2076 (72.3) 796 (27.7) 2750 (95.8) 122 (4.2)
  65–74 3814 (28.2) 2414 (63.3) 1400 (36.7) 3338 (87.5) 476 (12.5)
  75–84 1853 (13.7) 1131 (61.0) 722 (39.0) 1499 (80.9) 354 (19.1)
  ≥85 1422 (10.5) 918 (64.6) 504 (35.4) 941 (66.2) 481 (33.8)
Race <0.001 <0.001
  White 6906 (51.1) 5128 (74.3) 1778 (25.7) 6065 (87.8) 841 (12.2)
  Black 5571 (41.2) 3633 (65.2) 1938 (34.8) 5034 (90.4) 537 (9.6)
  Unknown 700 (5.2) 544 (77.7) 156 (22.3) 644 (92.0) 56 (8.0)
  Asian 130 (1.0) 102 (78.5) 28 (21.5) 119 (91.5) 11 (8.5)
  American Indian or Alaskan 
Native
104 (0.8) 80 (76.9) 24 (23.1) 91 (87.5) 13 (12.5)
  Native Hawaiian or other 
Pacific Islander
99 (0.7) 81 (81.8) 18 (18.2) 90 (90.9) 9 (9.1)
Ethnicity 0.089 <0.001
  Not Hispanic 12 262 (90.8) 8658 (70.6) 3604 (29.4) 10 889 (88.8) 1373 (11.2)
  Hispanic 1248 (9.2) 910 (72.9) 338 (27.1) 1154 (92.5) 94 (7.5)
Gender <0.001 <0.001
  Female 1239 (9.2) 1046 (84.4) 193 (15.6) 1205 (97.3) 34 (2.7)
  Male 12 270 (90.8) 8529 (69.4) 3749 (30.6) 10 837 (88.3) 1433 (11.7)
Medical history
  Hypertension <0.001 <0.001
   No 4815 (35.6) 3955 (82.1) 860 (17.9) 4486 (93.2) 329 (6.8)
   Yes 8695 (64.4) 5613 (64.6) 3082 (35.4) 7557 (86.9) 1138 (13.1)
  Diabetes <0.001 <0.001
   No 8334 (61.7) 6362 (76.3) 1972 (23.7) 7590 (91.1) 744 (8.9)
   Yes 5176 (38.3) 3206 (61.9) 1970 (38.1) 4453 (86.0) 723 (14.0)
  Chronic obstructive 
pulmonary disease
<0.001 <0.001
   No 10 322 (76.4) 7589 (73.5) 2733 (26.5) 9301 (90.1) 1021 (9.9)
   Yes 3188 (23.6) 1979 (62.1) 1209 (37.9) 2742 (86.0) 446 (14.0)
  Chronic kidney disease <0.001 <0.001
   No 11 047 (81.8) 8289 (75.0) 2758 (25.0) 10 081 (91.3) 966 (8.7)
   Yes 2463 (18.2) 1279 (51.9) 1184 (48.1) 1962 (79.7) 501 (20.3)
  Congestive heart failure <0.001 <0.001
   No 11 518 (85.3) 8516 (73.9) 3002 (26.1) 10 458 (90.8) 1060 (9.2)
   Yes 1992 (14.7) 1052 (52.8) 940 (47.2) 1585 (79.6) 407 (20.4)
  Atrial fibrillation <0.001 <0.001
   No 11 877 (87.9) 8651 (72.8) 3226 (27.2) 10 739 (90.4) 1138 (9.6)
   Yes 1633 (12.1) 917 (56.2) 716 (43.8) 1304 (79.8) 329 (20.2)
  Cancer <0.001 <0.001
   No 12 484 (92.4) 8996 (72.1) 3488 (27.9) 11 194 (89.7) 1290 (10.3)
   Yes 1026 (7.6) 572 (55.8) 454 (44.2) 849 (82.8) 177 (17.2)
  Myocardial infarction <0.001 <0.001
Continued












Died within 45 
days (n=1467)
P value
Column Row Row Row Row
N (%) N (%) N (%) N (%) N (%)
   No 12 701 (94.0) 9171 (72.2) 3530 (27.8) 11 403 (89.8) 1298 (10.2)
   Yes 809 (6.0) 397 (49.1) 412 (50.9) 640 (79.1) 169 (20.9)
Current smoker <0.001 <0.001
  No 11 231 (83.1) 8070 (71.8) 3161 (28.2) 9931 (88.4) 1300 (11.6)
  Yes 2279 (16.9) 1498 (65.7) 781 (34.3) 2112 (92.7) 167 (7.3)
Body mass index (kg/m2) <0.001 <0.001
  <25 2645 (19.6) 1564 (59.1) 1081 (40.9) 2187 (82.7) 458 (17.3)
  25–29 4036 (29.9) 2871 (71.1) 1165 (28.9) 3623 (89.8) 413 (10.2)
  30–34 3339 (24.7) 2458 (73.6) 881 (26.4) 3086 (92.4) 253 (7.6)
  ≥35 2601 (19.2) 1864 (71.7) 737 (28.3) 2384 (91.7) 217 (8.3)
  Missing 889 (6.6) 811 (91.2) 78 (8.8) 763 (85.8) 126 (14.2)
Long- term care facility
(prior 30 days)
<0.001 <0.001
  No 12 865 (95.2) 9194 (71.5) 3671 (28.5) 11 550 (89.8) 1315 (10.2)




  No 1012 (7.5) 736 (72.7) 276 (27.3) 845 (83.5) 167 (16.5)
  Yes 12 498 (92.5) 8832 (70.7) 3666 (29.3) 11 198 (89.6) 1300 (10.4)
Table 1 Continued
Figure 2 The figure displays the differences in the facility all- cause, 45- day mortality rates for COVID-19 patients: panel 
A includes 160 facilities with at least one patient with COVID-19; panel B includes 133 facilities with at least one COVID-19 
inpatient cared for on a general ward or critical care unit; panel C includes 115 facilities with at least one COVID-10 ICU patient; 
and panel D includes 90 facilities with at least one patient with COVID-19 who received mechanical ventilation.
7Bravata DM, et al. BMJ Open 2021;11:e044646. doi:10.1136/bmjopen-2020-044646
Open access
with extreme mortality rates (eg, 0% or 100% mechan-
ical ventilator mortality; figure 2, panel D) had very few 
patients.
Risk-adjusted mortality across VA facilities
The patient characteristics that were independently asso-
ciated with increased mortality included: increasing age, 
Asian race, diabetes, CKD, MI, CHF and residence in a 
long- term care facility (table 2, model 1). Patients who 
were admitted to the hospital, cared for in an ICU and 
those who received mechanical ventilation all had an 
higher odds of mortality compared with patients who 
were cared for entirely in the outpatient setting (table 2). 
The patient characteristics that were independently asso-
ciated with decreased mortality included: female gender, 
higher body mass index (≥25 kg/m2), being seen by a 
primary care provider within prior 2 years and current 
smoking status (table 2).
The patient admission category (models 3 and 4) 
demonstrated a robust and statistically significant associ-
ation with mortality: no admission (reference category), 
hospital admission without ICU or mechanical venti-
lation (OR1.25 (95% CI 1.04 to 1.500)), ICU without 
mechanical ventilation (OR 3.23 (95% CI 2.64 to 3.96)) 
and mechanical ventilation (OR 27.33 (95% CI 22.11 to 
33.77)). When patient admission category was included, 
two comorbidities (diabetes and CHF) from model 1 were 
no longer significantly associated with mortality (table 2).
The facility characteristics that were associated with 
mortality in bivariate analyses included: mean age at 
the facility, proportion of patients admitted to the ICU, 
proportion receiving mechanical ventilation, overall 
caseload and facility complexity (online supplemental 
figures B and C). When facility characteristics were 
included in the multivariable models (models 2 and 4), 
the patient level estimates were similar to those obtained 
in models 1 and 3. The only facility characteristics that 
was independently associated with COVID-19 mortality 
after risk adjustment for patient characteristics was an 
increasing proportion of patients with mechanical venti-
lation (table 2, model 2). The total number of patients 
with COVID-19 was not associated with mortality (table 2, 
models 2 and 4). Similarly, facility complexity and rural 
location were also not independently associated with 
mortality (table 2, models 2 and 4). In sensitivity analyses, 
the mixed effects logistic regression results were similar 
when excluding CLC patients and registry- only patients 
(online supplemental table A). The proportional hazard 
model results were also similar to the primary analysis. 
The C- statistic was 0.796 for model 1, 0.866 for model 2, 
0.868 for model 3 and 0.799 for model 4 (table 3).
Variation in mortality across VA facilities
Of the four multivariable models, model 2 with patient 
characteristics (excluding patient admission status) 
and facility characteristics reduced the variation most 
across facilities from 0.177 to 0.061 (table 3). However, 
the majority of the variance in mortality was accounted 
for by patient factors only (model 1): 0.177 to 0.074 is a 
58.2% reduction in variance. In contrast, the addition of 
facility characteristics to the multivariable modelling only 
reduced the variance in mortality from 0.074 (model 1) 
to 0.061 (model 2), which is a 7.3% reduction in variance. 
Including the patient- level variable for admission status 
to the model (model 3) increased the C- statistic from 
0.799 to 0.868; however, the variation across facilities also 
increased from 0.061 to 0.136.15
DISCUSSION
Although studies have examined differences in COVID-19 
prevalence16 or outcomes17 across geographic regions, 
few reports explicitly describe variation across facilities.1 
Substantial heterogeneity in caseload was observed across 
facilities within the VA system. We found that although 
observed mortality varied dramatically across facili-
ties, heterogeneity in facility mortality rates was likely 
primarily due to differences in patient characteristics (eg, 
age, comorbidities and clinical disease severity) rather 
than differences in facility characteristics (eg, ICU level). 
This finding is reassuring from a public health perspec-
tive because it indicates that outcomes for patients with 
COVID-19 were similar across the full spectrum of hospi-
tals from small, rural facilities without teaching services or 
research enterprises to large, academic centres.
The results are in alignment with the literature that has 
described the association between COVID-19 outcomes 
and patient factors (age in particular).18 19 Across all four 
of the multivariable models, the association between age 
and mortality among patients with COVID-19 was mono-
tonic and robust. Compared with younger patients (<55 
years old), patients ≥85 years old had a ≥38- fold increased 
odds of death within 45 days of the positive COVID-19 
laboratory test. These results support public health initia-
tives that seek to protect the elderly from exposure to 
COVID-19 given their very high risk of mortality.
The population that was the focus of this study, US 
Veterans, with a median age of 64.7 years was older than 
cohorts reported from China especially those evaluated 
early in the pandemic (median age was 46.2 years among 
43 studies included in a meta- analysis).20 However, when 
focusing on populations of patients with COVID-19 who 
were admitted to a hospital, this US Veteran population 
with COVID-19 was similar to a hospitalised popula-
tion from England where the median age was 72 years 
and 36.1% were ≥80 years of age.21 A study from Italy of 
patients hospitalised with COVID-19 reported a mean age 
of 67 years. Differences in age across populations may be 
a consequence of variation in testing practices. If hospi-
talised patients are more likely to be tested, and if older 
patients are more likely to be hospitalised, then regions 
with lower outpatient testing rates are expected to have 
overall older aged COVID-19 patient cohorts.
Our findings of variation of caseload across facilities 
is analogous to reports of geographic heterogeneity in 
disease prevalence.22 For example, a serological survey 
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Table 2 Mixed effects logistic regression modelling 45- day mortality among patients with COVID-19
Characteristics
Patients with COVID-19 (n=13 510 patients at n=160 facilities)
Patient characteristics only
Patient and facility 
characteristics
Patient characteristics and 
admission category
Patient and facility 
characteristics, and 
admission category


















Age (years) <0.001 <0.001 <0.001 <0.001
  <55 1 1 1 1
  55–64 3.98 (2.69 to 5.88) 3.95 (2.67 to 5.84) 3.33 (2.21 to 5.00) 3.29 (2.19 to 4.95)
  65–74 11.13 (7.71 to 16.07) 11.03 (7.63 to 15.94) 9.38 (6.41 to 13.73) 9.25 (6.32 to 13.55)
  75–84 17.80 (12.20 to 25.97) 17.56 (12.02 to 25.65) 17.12 (11.55 to 25.39) 16.86 (11.36 to 25.03)
  ≥85 38.73 (26.46 to 56.68) 38.23 (26.08 to 56.04) 43.89 (29.50 to 65.32) 43.06 (28.91 to 64.15)
Race 0.017 0.02 0.099 0.092
  American Indian or Alaskan 
Native
1.68 (0.88 to 3.22) 1.66 (0.86 to 3.19) 1.43 (0.68 to 3.01) 1.43 (0.67 to 3.01)
  Asian 2.46 (1.22 to 4.97) 2.43 (1.19 to 4.95) 2.22 (1.00 to 4.92) 2.29 (1.03 to 5.11)
  Black 1.14 (0.99 to 1.31) 1.14 (0.99 to 1.31) 0.91 (0.78 to 1.07) 0.93 (0.79 to 1.09)
  Native Hawaiian or other 
Pacific Islander
1.50 (0.71 to 3.15) 1.58 (0.75 to 3.32) 1.45 (0.63 to 3.32) 1.52 (0.66 to 3.48)
  Unknown 0.84 (0.62 to 1.15) 0.84 (0.62 to 1.15) 0.79 (0.57 to 1.10) 0.78 (0.56 to 1.08)
  White 1 1 1
Hispanic 1.05 (0.82 to 1.35) 0.676 1.05 (0.82 to 1.35) 0.691 0.96 (0.73 to 1.26) 0.767 0.97 (0.73 to 1.27) 0.802
Female 0.57 (0.39 to 0.82) 0.002 0.57 (0.40 to 0.83) 0.004 0.67 (0.46 to 0.99) 0.045 0.67 (0.46 to 0.99) 0.044
Medical history
  Hypertension 0.99 (0.84 to 1.17) 0.932 0.99 (0.84 to 1.17) 0.903 0.93 (0.77 to 1.11) 0.422 0.93 (0.78 to 1.12) 0.443
  Diabetes 1.22 (1.07 to 1.38) 0.003 1.21 (1.06 to 1.38) 0.004 1.13 (0.98 to 1.30) 0.102 1.12 (0.97 to 1.29) 0.112
  Chronic obstructive 
pulmonary disease
1.06 (0.92 to 1.21) 0.411 1.05 (0.92 to 1.21) 0.456 0.97 (0.84 to 1.13) 0.718 0.97 (0.84 to 1.13) 0.738
  Chronic kidney disease 1.39 (1.21 to 1.60) <0.001 1.39 (1.21 to 1.60) <0.001 1.34 (1.15 to 1.56) 0 1.35 (1.16 to 1.58) 0
  Atrial fibrillation 0.99 (0.84 to 1.16) 0.88 0.99 (0.85 to 1.16) 0.917 0.95 (0.80 to 1.13) 0.538 0.95 (0.80 to 1.13) 0.548
  Myocardial infarction 1.24 (1.01 to 1.52) 0.038 1.22 (1.00 to 1.50) 0.055 1.25 (1.00 to 1.56) 0.048 1.25 (1.00 to 1.56) 0.049
  Cancer 1.16 (0.96 to 1.39) 0.129 1.16 (0.96 to 1.40) 0.122 1.16 (0.95 to 1.42) 0.149 1.16 (0.95 to 1.42) 0.145
  Congestive heart failure 1.24 (1.06 to 1.46) 0.007 1.23 (1.05 to 1.45) 0.009 1.18 (0.99 to 1.40) 0.063 1.17 (0.98 to 1.39) 0.074
Body mass index (kg/m2) <0.001 <0.001 0.001 0.001
  <25 1 1 1 1
  25–29 0.82 (0.70 to 0.95) 0.82 (0.70 to 0.96) 0.80 (0.67 to 0.95) 0.80 (0.68 to 0.95)
  30–34 0.77 (0.64 to 0.92) 0.78 (0.65 to 0.93) 0.75 (0.62 to 0.92) 0.75 (0.62 to 0.92)
  ≥35 1.15 (0.94 to 1.40) 1.16 (0.95 to 1.41) 1.04 (0.84 to 1.30) 1.04 (0.84 to 1.30)
  Missing 0.94 (0.72 to 1.24) 0.96 (0.72 to 1.26) 1.18 (0.88 to 1.58) 1.17 (0.88 to 1.57)
Primary care within prior 
2 years
0.67 (0.53 to 0.85) 0.001 0.68 (0.54 to 0.86) 0.001 0.77 (0.60 to 0.99) 0.043 0.77 (0.60 to 0.99) 0.045
Community Living Centre: prior 
30 days
1.41 (1.12 to 1.76) 0.003 1.41 (1.03 to 1.95) 0.035 1.77 (1.39 to 2.25) <0.001 1.74 (1.37 to 2.23) <0.001
Current smoker 0.81 (0.67 to 0.97) 0.025 1.61 (1.16 to 2.22) 0.005 0.75 (0.62 to 0.93) 0.007 0.76 (0.62 to 0.93) 0.007
Patient admission category <0.001 <0.001
  No admission (reference) 1 1
  Hospital admission (not ICU, 
not mechanical ventilation)
1.25 (1.04 to 1.50) 1.29 (1.07 to 1.56)
  ICU (not mechanical 
ventilation)
3.24 (2.65 to 3.96) 3.40 (2.77 to 4.18)
  Mechanical ventilation 27.37 (22.14 to 33.83) 29.12 (23.42 to 36.21)
Facility- level characteristics
Continued
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from Spain reported substantial geographical variation, 
with higher prevalence near Madrid (>10%) and lower 
prevalence in coastal areas (<3%).23 A study from the USA 
reported higher COVID-19 mortality in rural versus urban 
communities; however, that study was limited to county- 
level (not patient level) data.24 In contrast, our results 
indicated that facility rurality was not independently asso-
ciated with COVID-19 patient mortality. The current study 
Characteristics
Patients with COVID-19 (n=13 510 patients at n=160 facilities)
Patient characteristics only
Patient and facility 
characteristics
Patient characteristics and 
admission category
Patient and facility 
characteristics, and 
admission category

















Number of patients with 
COVID-19
0.131 0.174
  <20 1.14 (0.69 to 1.87) 0.74 (0.42 to 1.31)
  20–49 1.40 (1.06 to 1.84) 1.27 (0.91 to 1.77)
  50–99 1.06 (0.84 to 1.34) 0.98 (0.74 to 1.30)
  ≥100 (reference) 1 1
Mean patient age 1.02 (1.00 to 1.04) 0.066 1.02 (0.99 to 1.04) 0.138
Percentage of patients 
admitted (no ICU, no vent)
0.95 0.779
  0 (reference) 1 1
  0.01–19.99 0.95 (0.68 to 1.33) 0.88 (0.59 to 1.32)
  20.0+ 0.95 (0.66 to 1.36) 0.86 (0.56 to 1.32)
Percentage of patients in ICU 
with mechanical ventilation
0.706 0.117
  0 (reference) 1 1
  0.01–9.99 1.10 (0.75 to 1.60) 1.07 (0.69 to 1.66)
  ≥10.0 1.02 (0.69 to 1.48) 0.82 (0.53 to 1.29)
Percent patients with 
mechanical ventilation
0.017 0.156
  0 (reference) 1 1
  0.01–4.99 1.41 (1.03 to 1.95) 1.03 (0.70 to 1.49)
  ≥5.0 1.61 (1.16 to 2.22) 0.80 (0.55 to 1.18)
Complexity 1a, 1b, 1c versus 
2 and 3
1.09 (0.81 to 1.47) 0.548 1.09 (0.76 to 1.56) 0.626
Rural facility 1.13 (0.77 to 1.66) 0.532 1.12 (0.72 to 1.76) 0.609
ICU, intensive care unit.
Table 2 Continued
Table 3 Random variation across facility 45- day mortality rates
Model
All patients (n=13 510 
patients at n=160 facilities)
VA laboratory patients* (excluded registry and 
CLC patients) (n=7535 patients at n=149 facilities)
C- statistic Variance (SE) Variance (SE)
Null model – 0.177 (0.043) 0.236 (0.067)
Model 1: patient characteristics only 0.796 0.074 (0.028) 0.081 (0.037)
Model 2: patient characteristics+facility characteristics 0.799 0.061 (0.026) 0.047 (0.031)
Model 3: patient characteristics+admission category† 0.866 0.160 (0.046) 0.190 (0.067)
Model 4: patient characteristics+admission 
category†+facility characteristics
0.868 0.136 (0.044) 0.170 (0.070)
*This sensitivity analysis included Veterans identified in the VA laboratory data only; Veterans identified only in the VA- NST registry and those who 
were Community Living Centre (CLC) residents in the 30 days prior to the COVID-19 positive test were excluded.
†Admission category refers to the setting where patients with COVID-19 received care: outpatient, admission to an inpatient ward, intensive care unit 
and mechanical ventilator.
VA- NST, VA National Surveillance Tool.
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adds to the existing literature by describing heterogeneity 
at the facility level within a national healthcare system.
Our finding that current smokers with COVID-19 were 
more likely to be admitted than non- smokers but that in 
multivariable modelling current smoking was associated 
with a lower risk of mortality is consistent with reports 
from cohorts in England,18 China25 and Italy,26 as well as 
an ecological study of 38 European countries.27 Although 
studies have suggested that nicotine exposure is related to 
ACE2 expression,28 and diseases associated with smoking 
such as COPD increase the risk of severe COVID-19 infec-
tion,29 the role of nicotine and smoking in COVID-19 
disease remains a topic of active investigation.
The results suggest that reported variation in unad-
justed mortality rates should be considered with caution 
and must be evaluated within the context of sample size 
and patient characteristics.1 For example, the overall 
in- hospital mortality rate of 18.2% among VA hospitals 
is somewhat higher than reports from the Kaiser Perma-
nente Northern California system of 15.6%, a healthcare 
system that cares for a younger cohort (mean age 61.0 
years compared with 63.5 years in the VA).30 Future studies 
of COVID-19 outcomes should include risk adjustment 
for relevant patient characteristics and should report 
C- statistics or other measures of model performance.
Limitations
Several potential limitations of this national cohort study 
merit description. First, we evaluated care of COVID-19 
positive Veteran patients at VA facilities; findings cannot 
be generalised to Veterans cared for in community 
(non- VA) facilities.31 Second, this study did not eval-
uate outcomes for non- COVID-19 patients at VA hospi-
tals; therefore, we did not evaluate the potential effects 
of COVID-19 on non- COVID-19 hospital operations.32 
Third, although a methodological strength of the study 
was the chart review validation of the administrative 
data, the outpatient mortality rates may still be underes-
timates because of delays in updating national VA death 
indices. Fourth, we do not have non- VA healthcare utili-
sation; therefore, patients may have received COVID-19 
testing within the VA but were subsequently hospitalised 
at a non- VA community hospital. Fifth, we described 
the proportion of patients who were treated in an ICU 
or received mechanical ventilation; we cannot comment 
on the appropriateness of such care. Sixth, we examined 
all- cause mortality in the 45- day period after COVID-19 
testing. Although it is likely that death among patients 
with COVID-19 was attributable to COVID-19 disease, 
some patients may have died from other causes (eg, pre- 
existing illness). Seventh, US Veterans are predominantly 
male, which may limit generalisability of findings to non- 
Veteran populations. Finally, although many key patients 
and facility characteristics were included in the analyses, 
there are many potential factors that may contribute 
to mortality among patients with COVID-19 including 
patient characteristics (eg, occupation) and facility 
characteristics (eg, environmental factors) that were not 
included in the multivariable modelling.
Conclusions
In this national cohort of 13 510 US Veterans with a posi-
tive COVID-19 test during the period March–31 May 2020 
across 160 VA facilities, marked heterogeneity in patient 
volume, admissions to the hospital and to the ICU, 
mechanical ventilation and 45- day, all- cause mortality 
were observed across VA facilities. However, after adjust-
ment for differences in patient characteristics, mortality 
was similar across VA facilities nationwide.
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